Business Trends– category –
-
ASE Initiates Largest-Ever Global Expansion to Double CoWoS Capacity to 45,000 Wafers/Month by Late 2027
Industry Blog/Analysis International Overview ASE is undertaking its largest global factory expansion in history, commencing construction of six new packaging and testing plants in 2026. This aggressive ramp aims to increase monthly CoWo... -
Galmed Pioneers Cardiac-Targeted LNP for Fibrosis, Repurposing Aramchol with Precision
GlobeNewswire via Galmed Israel Overview Galmed, in collaboration with Barcode Nanotech, has engineered a novel lipid nanoparticle (LNP) formulation for its SCD1 inhibitor, Aramchol. This innovation enables precise, heart-targeted delive... -
Cytovance Biologics Enhances Biologics Manufacturing Process Development with Perfusion Capabilities to Boost Productivity
Cytovance Biologics USA Overview Cytovance Biologics, a CDMO, has expanded its upstream process development services by integrating perfusion capabilities. This technological addition enables higher productivity, extended cell culture du... -
Monte Rosa Therapeutics’ NEK7 Molecular Glue Degrader MRT-8102/8120 Shows 85% CRP Reduction in Cardiovascular Risk Patients in Positive Phase 1 Interim Data
AllMind AI News USA Overview Monte Rosa Therapeutics reported positive interim Phase 1 data for its NEK7-directed molecular glue degrader, MRT-8102/8120, demonstrating an 85% median reduction in C-reactive protein (CRP) over 4 weeks in c... -
Denali Therapeutics Announces Breakthroughs in Blood-Brain Barrier Biologic Delivery: AVLAYAH™ Receives FDA Accelerated Approval for Hunter Syndrome
Denali Therapeutics USA Overview Denali Therapeutics CEO Dr. Ryan Watts will deliver a plenary address at AAIC 2026, highlighting the company's breakthrough advancements in delivering biologic therapies across the blood-brain barrier (BB... -
Nava Therapeutics Raises $89 Million for Lipid Nanoparticle (LNP) Platform: Innovating RNA Therapeutic Delivery
Endpoints News USA Overview Nava Therapeutics announced the completion of an $89 million Series A funding round to advance its lipid nanoparticle (LNP) platform, specialized in efficient RNA-based therapeutic delivery. This substantial f... -
RNAi Therapeutics Advance in Metabolic Disease Treatment with Liver-Targeted DDS and Emerging Self-Delivery siRNAs
ResearchGate (Trends in Pharmacological Sciences) Unknown Overview This article discusses RNA interference (RNAi) as a therapeutic strategy for metabolic diseases, emphasizing its advantage in targeting virtually all genes. Despite deliv... -
FDA Accepts Shionogi’s sNDA for Fetroja® (cefiderocol) in Pediatric Patients with Serious Gram-Negative Infections
Shionogi Japan Overview The FDA has accepted Shionogi's supplemental New Drug Application (sNDA) for Fetroja® (cefiderocol) to treat serious infections caused by susceptible Gram-negative bacteria in pediatric patients. This submission a... -
Ractigen’s SOD1-ALS siRNA Therapy RAG-17 Shows Significant SOD1 Reduction and Favorable Safety in Phase 1, Published in Nature Medicine
BioSpace USA Overview Ractigen Therapeutics published preclinical and positive First-in-Human Phase 1 clinical data for RAG-17, an siRNA therapy for SOD1-ALS, in Nature Medicine. The trial met primary safety endpoints with no serious adv... -
Solid-State Battery Manufacturing Advances to Pilot Lines, Automotive Programs, and Vehicle Testing: QuantumScape and Honda Strengthen Collaboration
XWELL International Overview Solid-state battery development in 2026 is shifting from laboratory breakthroughs to practical, manufacturing-focused stages. The industry is now concentrating on building pilot production lines, integrating ...
